{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:13:43Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 15.8, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09551-9b93-7f50-bab0-edd3efe0a90c\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: meglitinide\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 74.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09551-9ba1-7083-bf92-636d769e6d3a\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: meglitinide\nRegistry id: vr.tr.meglitinide\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:51:20+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "revisions": [ { "at": "2026-10-07T11:32:49+00:00", "engine": "codex", "fields": [ "definition", "distinguishing_features", "in_scope", "out_of_scope", "purpose", "scope_statement" ], "answering_review": "3acac5c971042e72098cb78df7996ec63c10488ad202d1c2ad9cab8d4eece9a0" } ], "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T12:16:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q412926", "registryId": "vr.tr.meglitinide", "name": "meglitinide", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q412926/", "model": { "registry_id": "vr.tr.meglitinide", "name": "meglitinide", "purpose": "Enable an agent to identify the meglitinide drug class and its members, explain their shared pharmacological role and distinguish class-level information from evidence about individual medicines.", "definition": "Meglitinides are a class of short-acting, non-sulfonylurea insulin-secretagogue drugs that stimulate insulin release from pancreatic beta cells and are used to treat type 2 diabetes.", "scope_statement": "This model owns the meglitinide drug class, its membership, shared pharmacological properties and limits on transferring evidence between members; it does not model the individual parent compound as the class itself.", "in_scope": [ "Class identity includes its distinction from the individual compound named meglitinide.", "Class membership includes medicines such as repaglinide and nateglinide.", "Shared pharmacology includes stimulation of pancreatic beta-cell insulin release.", "Class-level information includes therapeutic roles, hypoglycaemia risks and relevant interactions.", "Evidence interpretation distinguishes shared class properties from member-specific indications, warnings and regulatory status." ], "out_of_scope": [ "The individual parent compound's molecular identity and material properties are outside scope.", "Complete independent substance models for individual class members are outside scope.", "Finished medicinal products, formulations and commercial packaging are outside scope.", "Patient-specific diabetes diagnosis, prescribing and dosing are outside scope.", "Manufacturing processes and laboratory equipment as independently modelled things are outside scope." ], "distinguishing_features": [ "The referent is a drug class rather than a single molecular structure.", "Members are short-acting insulin secretagogues that act on pancreatic beta cells.", "The class is distinct from sulfonylureas despite sharing the ability to stimulate insulin release.", "A class designation does not assign the parent compound's molecular identifiers to every member.", "Evidence about one member does not automatically establish the same indication, interaction or regulatory status for all members." ], "characteristics": [ { "name": "Registry referent resolution", "kind": "state", "unit_or_values": "individual compound confirmed | drug class confirmed | unresolved", "why_it_matters": "Determines whether molecular constants and material-state assessments belong to this entry." }, { "name": "Structure and identifier agreement", "kind": "relation", "unit_or_values": "Registry source linked to verified structure, PubChem CID, CAS number, and EC number where established", "why_it_matters": "Prevents similarly named drugs or class records from being merged into the compound." }, { "name": "Chemical form", "kind": "category", "unit_or_values": "parent compound | specified salt | specified solvate or hydrate | mixture | unresolved", "why_it_matters": "Identity, mass calculations, solubility, and measured properties depend on the actual form." }, { "name": "Meglitinide content and impurity profile", "kind": "measurement", "unit_or_values": "mass fraction %, chromatographic area %, or molar concentration, with method and uncertainty", "why_it_matters": "Separates usable compound content from method-dependent purity estimates and confounding impurities." }, { "name": "Phase and thermal behavior", "kind": "measurement", "unit_or_values": "phase at stated temperature and pressure; melting or decomposition interval in °C", "why_it_matters": "Supports recognition of material changes without assuming a reported transition applies to every form." }, { "name": "Solubility and solution condition", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with solvent, pH, temperature, equilibration time, and chemical form", "why_it_matters": "Determines whether experimental exposure reflects dissolved meglitinide or an unstable suspension." }, { "name": "Compound-specific biological activity", "kind": "measurement", "unit_or_values": "assay endpoint, concentration-response, and IC50 or EC50 in mol/L where applicable", "why_it_matters": "Connects activity claims to the tested material, biological system, and experimental conditions." }, { "name": "Handling and use evidence", "kind": "state", "unit_or_values": "supported | restricted | unresolved, separately for each proposed action and jurisdiction", "why_it_matters": "Prevents class-level therapeutic familiarity from being treated as authorization to use this compound." } ], "affordances": [ "Resolve whether a supplied record identifies the compound or the drug class.", "Compare a material's analytical identity with a verified meglitinide reference.", "Assess whether purity, chemical form, and solution condition support a proposed experiment.", "Separate compound-specific biological evidence from evidence about other glinides.", "Identify missing handling, stability, or authorization evidence before approving a proposed use." ], "agent_conduct": { "may": [ "Explain what meglitinide and the meglitinide drug class are, citing pharmacology sources.", "Report approved products in the class, their indications and warnings from official labelling." ], "must_not": [ "Recommend, dose or adjust a meglitinide-class medicine for a specific person.", "Advise anyone to obtain or use glucose-lowering drugs without a prescription.", "Help use a glucose-lowering drug to harm someone.", "Present the parent compound as an approved medicine where it is not." ], "requires_human": [ "Starting, stopping or changing any glucose-lowering treatment for a patient." ] }, "ethics": { "considerations": [ "Glucose-lowering drugs can cause dangerous low blood sugar.", "People with diabetes rely on accurate drug information." ], "affected_parties": [ "Patients with diabetes", "Prescribers and pharmacists", "Carers" ] }, "owners": { "steward": "The prescriber and the pharmacist for each patient; medicines regulators authorize products.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identified by product label, active ingredient name and batch records rather than appearance." ], "failure_modes_and_hazards": [ "Low blood sugar, especially if a meal is skipped.", "Interactions with other medicines.", "Misuse to cause harm." ], "what_it_is_for": [ "Meglitinides are encountered in type 2 diabetes care as oral medicines that stimulate pancreatic insulin release.", "The class is also studied in pharmacology to investigate insulin secretion and glucose regulation.", "The parent compound and individual medicines in the class require separate identification because their evidence and approved uses differ." ], "standards_and_regulation": [ "The WHO Collaborating Centre for Drug Statistics Methodology classifies the meglitinide medicines repaglinide and nateglinide within ATC group A10BX for other blood glucose lowering drugs excluding insulins.", "The European Parliament and Council's Directive 2001/83/EC governs human medicinal products containing meglitinide medicines within its scope." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q412926: meglitinide", "url": "https://www.wikidata.org/wiki/Q412926", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Meglitinide", "url": "https://en.wikipedia.org/wiki/Meglitinide", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "meglitinide-referent-and-identity", "name": "Meglitinide referent and identity", "description": "Resolve the ambiguous name and establish the molecular identity owned by this registry entry.", "rationale": "A molecular compound and the similarly named drug class require different models and cannot share one set of substance constants.", "layers": [ { "id": "registry-referent", "name": "Registry referent", "description": "Determine what the originating registry record actually denotes.", "findings": [ { "id": "compound-or-class", "name": "Compound or class", "description": "The draft treats the individual compound as a provisional referent; the missing registry definition leaves that interpretation unsettled.", "questions": [ { "text": "Does the originating registry identifier denote the individual molecule or the meglitinide drug class?", "kind": "boundary", "id": "compound-or-class-q01" }, { "text": "Which source record, definition, and identifier relationships establish that interpretation?", "kind": "provenance", "id": "compound-or-class-q02" } ] } ] }, { "id": "molecular-reference", "name": "Molecular reference", "description": "Anchor the compound interpretation in structure and consistent identifiers.", "findings": [ { "id": "verified-meglitinide-structure", "name": "Verified meglitinide structure", "description": "PubChem lists an individual meglitinide compound as CID 41214 with formula C17H16ClNO4; this is a candidate reference, not proof of the registry's intended referent. Source: [PubChem Meglitinide](https://pubchem.ncbi.nlm.nih.gov/compound/Meglitinide).", "questions": [ { "text": "Which canonical structure and InChIKey identify the intended meglitinide compound?", "kind": "definition", "id": "verified-meglitinide-structure-q01" }, { "text": "Which CAS and EC identifiers can be verified against that same structure rather than against a class or related drug?", "kind": "provenance", "id": "verified-meglitinide-structure-q02" } ] } ] } ] }, { "id": "meglitinide-material-fitness", "name": "Meglitinide material fitness", "description": "Assess whether a physical sample contains the intended compound in a characterized, usable state.", "rationale": "A correct name does not establish chemical form, content, or suitability for biological measurements.", "layers": [ { "id": "form-and-composition", "name": "Form and composition", "description": "Record the actual chemical form and analytically supported composition.", "findings": [ { "id": "sample-identity-and-content", "name": "Sample identity and content", "description": "Require sample-specific identity and content evidence before attributing an observation to meglitinide.", "questions": [ { "text": "Is the sample the parent compound, a specified salt or solvate, or a mixture containing meglitinide?", "kind": "boundary", "id": "sample-identity-and-content-q01" }, { "text": "Which identity tests and quantitative methods establish meglitinide content, residual solvents, and relevant impurities?", "kind": "measurement", "id": "sample-identity-and-content-q02" } ] } ] }, { "id": "physical-and-solution-state", "name": "Physical and solution state", "description": "Characterize the material under storage and experimental conditions.", "findings": [ { "id": "state-dependent-usability", "name": "State-dependent usability", "description": "Treat thermal behavior, solubility, and stability as conditional measurements; no universal numerical values are assumed.", "questions": [ { "text": "What phase, melting or decomposition behavior, and storage stability are measured for this specific form of meglitinide?", "kind": "measurement", "id": "state-dependent-usability-q01" }, { "text": "At the proposed solvent, pH, temperature, and concentration, does meglitinide remain dissolved and chemically intact for the required duration?", "kind": "measurement", "id": "state-dependent-usability-q02" } ] } ] } ] }, { "id": "meglitinide-biological-evidence", "name": "Meglitinide biological evidence", "description": "Evaluate biological claims made about the individual compound and distinguish them from claims about the glinide class.", "rationale": "Name overlap makes it especially easy to import another drug's mechanism, potency, or clinical behavior into this entry.", "layers": [ { "id": "tested-compound-attribution", "name": "Tested compound attribution", "description": "Connect every activity claim to a clearly identified test article.", "findings": [ { "id": "direct-meglitinide-evidence", "name": "Direct meglitinide evidence", "description": "Use proposed insulin-secretagogue and potassium-channel effects as research questions until direct compound-specific evidence is established.", "questions": [ { "text": "Which primary experiments tested the individual meglitinide compound, with sufficient identifiers to exclude repaglinide or another glinide?", "kind": "provenance", "id": "direct-meglitinide-evidence-q01" }, { "text": "What direct evidence establishes effects on ATP-sensitive potassium channels, receptor binding, or insulin secretion for that test article?", "kind": "measurement", "id": "direct-meglitinide-evidence-q02" } ] } ] }, { "id": "assay-context-and-transfer", "name": "Assay context and transfer", "description": "Bound what a biological result supports beyond its original experimental setting.", "findings": [ { "id": "activity-context", "name": "Activity context", "description": "Assess potency and functional effects together with exposure, biological system, and controls rather than treating a class description as a compound measurement.", "questions": [ { "text": "What species, cell system, glucose condition, dissolved concentration, exposure duration, and controls underpin the reported response?", "kind": "measurement", "id": "activity-context-q01" }, { "text": "Which conclusions remain limited to the assay, and which have direct evidence in intact organisms or humans?", "kind": "boundary", "id": "activity-context-q02" } ] } ] } ] }, { "id": "meglitinide-handling-and-use", "name": "Meglitinide handling and use", "description": "Determine which actions are supported for the identified compound and material.", "rationale": "Medicinal use of related glinides does not establish this compound's hazard classification, approval, or experimental suitability.", "layers": [ { "id": "compound-specific-hazards", "name": "Compound-specific hazards", "description": "Establish handling requirements using evidence applicable to the actual meglitinide material.", "findings": [ { "id": "hazard-evidence-and-gaps", "name": "Hazard evidence and gaps", "description": "Keep verified classifications, biological hazard evidence, and missing information distinct; an absent classification does not establish absence of hazard.", "questions": [ { "text": "Which safety data sheet and jurisdiction-specific GHS classifications match this compound, chemical form, and supplied material?", "kind": "provenance", "id": "hazard-evidence-and-gaps-q01" }, { "text": "What compound-specific evidence supports exposure controls, spill response, disposal requirements, or an occupational exposure limit?", "kind": "action", "id": "hazard-evidence-and-gaps-q02" } ] } ] }, { "id": "permitted-use-and-readiness", "name": "Permitted use and readiness", "description": "Separate the intended action from the evidence and authorization needed to perform it.", "findings": [ { "id": "use-decision", "name": "Use decision", "description": "Evaluate research and medicinal-use claims for the exact compound without inheriting permissions or dosing practices from other meglitinides.", "questions": [ { "text": "What authoritative record establishes any research restrictions or medicinal authorization for this exact compound in the relevant jurisdiction and date?", "kind": "provenance", "id": "use-decision-q01" }, { "text": "Does the proposed experiment have adequate identity, purity, stability, biological-evidence, and handling support, or which missing evidence prevents proceeding?", "kind": "action", "id": "use-decision-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "First verify whether the registry intends the individual compound or the therapeutic class; no sense is recorded.", "Confirm the original compound's authoritative chemical identifiers, composition and physical properties before adding substance-level data.", "Clinical indications, doses and regulatory approvals of repaglinide or nateglinide should not be attributed to the original meglitinide compound." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of meglitinide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Pharmacological research into the stimulation of insulin secretion.", "Historical reference compound for the development of related insulin secretagogues." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of meglitinide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Insulin-secretagogue activity can cause hypoglycaemia.", "Confusing the original compound with the drug class can lead to assigning the properties, clinical uses or approvals of related drugs to meglitinide itself." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of meglitinide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "meglitinides", "difference": "The plural denotes a therapeutic drug class; meglitinide also names the individual compound from which the class takes its name." }, { "name": "repaglinide", "difference": "A distinct active pharmaceutical ingredient in the meglitinide class, used to treat type 2 diabetes." }, { "name": "nateglinide", "difference": "A distinct, phenylalanine-derived insulin secretagogue commonly grouped with the meglitinides." }, { "name": "sulfonylureas", "difference": "These insulin secretagogues possess a sulfonylurea chemical group; meglitinide lacks that group despite related effects on beta-cell ATP-sensitive potassium channels." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of meglitinide this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does vr.tr.meglitinide refer to the individual compound or the drug class, and does an existing Vercy model already own that referent?", "Which structure, CAS number, EC number, and synonyms are verified for the intended registry referent?", "Which primary studies establish biological activity for the individual compound rather than for related glinides?", "What measured purity, solubility, thermal, and stability data exist for identifiable meglitinide material and chemical forms?", "What compound-specific hazard classifications, exposure limits, and regulatory or medicinal-use records can be verified?" ], "statistics": { "bundles": 5, "layers": 9, "findings": 12, "questions": 20 } }